Patrick Dallemagne

4.0k total citations · 1 hit paper
147 papers, 3.0k citations indexed

About

Patrick Dallemagne is a scholar working on Organic Chemistry, Molecular Biology and Pharmacology. According to data from OpenAlex, Patrick Dallemagne has authored 147 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Organic Chemistry, 56 papers in Molecular Biology and 40 papers in Pharmacology. Recurrent topics in Patrick Dallemagne's work include Cholinesterase and Neurodegenerative Diseases (31 papers), Chemical synthesis and alkaloids (20 papers) and Computational Drug Discovery Methods (19 papers). Patrick Dallemagne is often cited by papers focused on Cholinesterase and Neurodegenerative Diseases (31 papers), Chemical synthesis and alkaloids (20 papers) and Computational Drug Discovery Methods (19 papers). Patrick Dallemagne collaborates with scholars based in France, Italy and Egypt. Patrick Dallemagne's co-authors include Christophe Rochais, Sylvain Rault, Ronan Bureau, Jean‐Pierre Jourdan, Michel Boulouard, Jean Guillon, Serge Mignani, Thomas Fréret, Amanda Garrido and Alban Lepailleur and has published in prestigious journals such as Proceedings of the National Academy of Sciences, SHILAP Revista de lepidopterología and Scientific Reports.

In The Last Decade

Patrick Dallemagne

140 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Drug repositioning: a brief overview

2020 304 citations Jean‐Pierre Jourdan, Ronan Bureau et al. Journal of Pharmacy and Pharmacology profile →

Peers

Countries citing papers authored by Patrick Dallemagne

Since Specialization

Citations

This map shows the geographic impact of Patrick Dallemagne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Dallemagne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Dallemagne more than expected).

Fields of papers citing papers by Patrick Dallemagne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Dallemagne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Dallemagne. The network helps show where Patrick Dallemagne may publish in the future.

Co-authorship network of co-authors of Patrick Dallemagne

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Dallemagne. A scholar is included among the top collaborators of Patrick Dallemagne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Dallemagne. Patrick Dallemagne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Preventing neuropathy and improving anticancer chemotherapy with a carbazole-based compound 2025 ·Science Advances ·(unknown), Maria Elena Pero, David Balayssac, (unknown), (unknown), (unknown), Julien Vollaire, Cécile Cottet‐Rousselle, (unknown), (unknown), Sakina Torch, (unknown), Bénédicte Elena‐Herrmann, Uwe Schlattner, (unknown), Véronique Josserand, Chantal Thibert, Patrick Dallemagne, Francesca Bartolini, Laurence Lafanéchère	0
2	Targeting together cholinesterases and serotonin reuptake against Alzheimer’s disease 2025 ·Journal of Pharmacy and Pharmacology ·(unknown), Cédric Lecoutey, Christophe Rochais, Patrick Dallemagne	0
3	Synthesis, in vitro and in vivo biological evaluation of novel dual compounds targeting both acetylcholinesterase and serotonergic 5-HT4 receptors with potential interest in the treatment of Alzheimer's disease 2024 ·European Journal of Medicinal Chemistry ·Christophe Rochais, Cédric Lecoutey, (unknown), Audrey Davis, (unknown), Florence Gaven, (unknown), (unknown), Sophie Corvaisier, Jana Sopková‐de Oliveira Santos, Marc Since, Thomas Fréret, Romain Legrand, Noëlle Callizot, Sylvie Claeysen, Michel Boulouard, Patrick Dallemagne	0
4	Development of Pleiotropic TrkB and 5-HT4 Receptor Ligands as Neuroprotective Agents 2024 ·Molecules ·(unknown), (unknown), Audrey Davis, (unknown), María Valcárcel, Isbaal Ramos, Patricia Villacé, Sylvie Claeysen, Patrick Dallemagne, Achille Gravanis, Ioannis Charalampopoulos, Christophe Rochais	3
5	Design, synthesis and biological characterization of novel activators of the TrkB neurotrophin receptor 2023 ·European Journal of Medicinal Chemistry ·(unknown), (unknown), Isbaal Ramos, María Valcárcel, Achille Gravanis, Patricia Villacé, Noëlle Callizot, Marc Since, Patrick Dallemagne, Ioannis Charalampopoulos, Christophe Rochais	5
6	Conceptual Framework of the Design of Pleiotropic Drugs against Alzheimer’s Disease 2023 ·Pharmaceutics ·(unknown), Cédric Lecoutey, Christophe Rochais, Patrick Dallemagne	7
7	Biginelli Reaction Synthesis of Novel Multitarget-Directed Ligands with Ca2+ Channel Blocking Ability, Cholinesterase Inhibition, Antioxidant Capacity, and Nrf2 Activation 2022 ·Molecules ·R.S. Malek, (unknown), Audrey Davis, Maciej Maj, Paul J. Bernard, Artur Wnorowski, Hélène Martin, José Marco‐Contelles, Fakher Chabchoub, Patrick Dallemagne, Christophe Rochais, Krzysztof Jóźwiak, Lhassane Ismaïli	9
8	Advances in prodrug design for Alzheimer’s disease: the state of the art 2022 ·Expert Opinion on Drug Discovery ·(unknown), Serge Mignani, Patrick Dallemagne, Christophe Rochais	3
9	Aminothiaindanone as an Accessible Scaffold for a Three-Point Chemical Diversity 2021 ·Synthesis ·Patrick Dallemagne, (unknown), (unknown), Jana Sopková‐de Oliveira Santos, Christophe Rochais	0
10	Active Targeted Nanoemulsions for Repurposing of Tegaserod in Alzheimer’s Disease Treatment 2021 ·Pharmaceutics ·(unknown), (unknown), (unknown), Pascal Verdié, Audrey Davis, Sophie Corvaisier, Vincent Lisowski, Patrick Dallemagne, Anne‐Claire Groo, Aurélie Malzert‐Fréon	9
11	Matrix Metalloproteinases as New Targets in Alzheimer’s Disease: Opportunities and Challenges 2020 ·Journal of Medicinal Chemistry ·(unknown), Christophe Rochais, Kévin Baranger, Santiago Rivera, Patrick Dallemagne	65
12	Drug repositioning: a brief overview breakdown → 2020 ·Journal of Pharmacy and Pharmacology ·Jean‐Pierre Jourdan, Ronan Bureau, Christophe Rochais, Patrick Dallemagne	304
13	Pharmacotechnical Development of a Nasal Drug Delivery Composite Nanosystem Intended for Alzheimer’s Disease Treatment 2020 ·Pharmaceutics ·(unknown), Anne‐Claire Groo, Céline Picard, Audrey Davis, Sophie Corvaisier, Marc Since, Fréderic Bounoure, Christophe Rochais, Loïc Le Pluart, Patrick Dallemagne, Aurélie Malzert‐Fréon	60
14	Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis 2020 ·European Journal of Medicinal Chemistry ·(unknown), Mena Cimino, (unknown), Cédric Lecoutey, (unknown), Noelia Alonso‐Rodríguez, Julien Briffotaux, Damien Mornico, Brigitte Gicquel, Christophe Rochais, Patrick Dallemagne	9
15	First Synthesis of Racemic Trans Propargylamino-Donepezil, a Pleiotrope Agent Able to Both Inhibit AChE and MAO-B, with Potential Interest against Alzheimer’s Disease 2020 ·Molecules ·(unknown), Cédric Lecoutey, Rémi Legay, Audrey Davis, Jana Sopková‐de Oliveira Santos, Cosimo Altomare, Marco Catto, Christophe Rochais, Patrick Dallemagne	16
16	Therapeutic modulators of the serotonin 5-HT ₄ receptor: a patent review (2014-present) 2020 ·Expert Opinion on Therapeutic Patents ·(unknown), Patrick Dallemagne, Cédric Lecoutey, Sylvie Claeysen, Christophe Rochais	11
17	Inhibiting Acetylcholinesterase to Activate Pleiotropic Prodrugs with Therapeutic Interest in Alzheimer’s Disease 2019 ·Molecules ·(unknown), Cédric Lecoutey, (unknown), (unknown), Audrey Davis, Marc Since, Sophie Corvaisier, Thomas Fréret, Jana Sopková‐de Oliveira Santos, Sylvie Claeysen, Michel Boulouard, Patrick Dallemagne, Christophe Rochais	20
18	Novel multitarget-directed ligands targeting acetylcholinesterase and σ1 receptors as lead compounds for treatment of Alzheimer's disease: Synthesis, evaluation, and structural characterization of their complexes with acetylcholinesterase 2018 ·European Journal of Medicinal Chemistry ·(unknown), Gianluca Santoni, Delphine Karila, Cédric Lecoutey, Audrey Davis, Florian Nachon, Israel Silman, Joel L. Sussman, Martin H. Weik, Tangui Maurice, Patrick Dallemagne, Christophe Rochais	39
19	Benzylphenylpyrrolizinones with Anti‐amyloid and Radical Scavenging Effects, Potentially Useful in Alzheimer's Disease Treatment 2017 ·ChemMedChem ·Jean‐Pierre Jourdan, Marc Since, Laïla El Kihel, Cédric Lecoutey, Sophie Corvaisier, Rémi Legay, Jana Sopková‐de Oliveira Santos, Thierry Cresteil, Aurélie Malzert‐Fréon, Christophe Rochais, Patrick Dallemagne	9
20	Synthesis and preliminaryin vivoevaluation of new 2-Aryl-6-methyl-1,2-dihydro-1H-pyridin-4-ones and 2-Aryl-6-methylpiperidin-4-ols, as potential anti-amnesiant agents 2005 ·Journal of Enzyme Inhibition and Medicinal Chemistry ·(unknown), Thomas Fréret, Michel Boulouard, Patrick Dallemagne, Sylvain Rault	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact